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Abstract
Background: Skeletal metastases are often accompanied by bone pain. To investigate the clinical meaning of
bone pain associated with skeletal metastasis in breast cancer patients after surgery, we explored whether the
presence of bone pain was due to skeletal-related events (SREs) or survival (cause specific death, CSD),
retrospectively.
Methods: Consecutive breast cancer patients undergoing surgery between 1988 and 1998 were examined for
signs of skeletal metastasis until December 2006. Patients who were diagnosed as having skeletal metastasis were
the subjects of this study. Bone scans were performed annually for 5, 7 or 10 years; they were also conducted if
skeletal metastasis was suspected. Data concerning bone pain and tumor markers at the time of skeletal metastasis
diagnosis, and data relating to various factors including tumors, lymph nodes and hormone receptors at the time
of surgery, were investigated. The relationships between factors such as bone pain, SRE and CSD were analyzed
using the Kaplan-Meier method and Cox’s analysis.
Results: Skeletal metastasis occurred in 668 patients but the pain status of two patients was unknown, therefore
666 patients were included in the study. At the time of skeletal metastasis diagnosis 270 patients complained of
pain; however, 396 patients did not. Analysis of data using Cox’s and Kaplan-Meier methods demonstrated that
patients without pain had fewer SREs and better survival rates than those with pain. Hazard ratios regarding SRE
(base = patients without pain) were 2.331 in univariate analysis and 2.243 in multivariate analysis. Hazard ratios
regarding CSD (base = patients without pain) were 1.441 in univariate analysis and 1.535 in multivariate analysis.
Similar results were obtained when analyses were carried out using the date of surgery as the starting point.
Conclusion: Bone pain at diagnosis of skeletal metastasis was an indicator of increased SRE and CSD. However,
these data did not support recommendations of follow-up bone surveys in breast cancer patients.
Background
Skeletal metastasis is a common complication of breast
cancer; more than 70% of patients who die from breast
cancer exhibit osseous metastasis at autopsy [1]. How-
ever, the high incidence of metastasis at autopsy is not
considered sufficient evidence to perform routine bone
surveys on breast cancer patients [2]. The reason given
is that there is no evidence that such surveys would
improve patients’ survival and quality of life [3-5].
There have been significant advancements in hormone
therapy and chemotherapy for advanced breast cancer
sufferers [6-8]. Furthermore, use of bisphosphonates to
treat skeletal metastasis associated with breast cancer
has been developed. Bisphosphonates reduce skeletal-
related events (SREs) in patients with skeletal metastasis
[9-13]. An analysis of the first appearance of skeletal
metastasis in breast cancer patients revealed that
patients with a solitary metastasis to bone (solitary bone
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skeletal metastases (multiple bone lesions) [14]. These
results suggest that early diagnosis of skeletal metastasis
and treatment with bisphosphonates could improve a
patient’s quality of life by reducing the number of skele-
tal complications. There have been many studies investi-
gating skeletal metastasis in breast cancer patients but
most of these were conducted before the emergence of
therapies such as bisphosphonates.
Pain is an important indicator of the presence of skeletal
metastasis [15]. However, no clinical symptoms are evi-
dent in the early phase of skeletal metastasis. There are
many prognostic factors related to survival, cause specific
death (CSD). The relationship between these factors and
SRE is not fully understood. Bone pain is a symptom pro-
duced by skeletal metastasis that could be related to SRE.
The aim of the present retrospective study was to clarify
the clinical meaning of bone pain at diagnosis of skeletal
metastasis by investigating the relationship of pain to SRE
and survival, and comparing this with other factors.
Methods
Patients
Breast cancer patients undergoing surgery at the Cancer
Institute Hospital, Tokyo, Japan, between January 1988
and December 1998 formed the patient pool, and were fol-
lowed up until December 2006. As the aim of this study
was to clarify skeletal metastasis after surgery, patients
with skeletal metastasis at the time of surgery were
excluded from the pool (5429 eligible patients). Six hun-
dred and sixty-eight patients developed skeletal metastasis
during the duration of the study. The follow-up protocol
after surgery was as follows: patients visited hospital and
received a physical check every three months for the first
two years, every six months thereafter until five years had
elapsed, and then annually after that. Patients who
received adjuvant therapy were followed up more fre-
quently. Bone scanning was used to confirm the presence
of skeletal metastasis; it was performed at the time of sur-
gery for staging purposes, annually thereafter for five
years, and then seven and 10 years after the date of sur-
gery. Bone scanning was also performed if physicians sus-
pected the presence of skeletal metastasis or wanted to
exclude it as a possibility. In the event of positive or equi-
vocal bone scans, other imaging techniques including
X-ray, computed tomography and magnetic resonance
imaging were used to confirm the diagnosis. The above
procedures were conducted as routine clinical practice at
the Cancer Institute Hospital, Tokyo, Japan.
Pain and the values of tumor marker at the diagnosis of
skeletal metastasis
T h ep r e s e n c eo fb o n ep a i na tt h et i m eo fd i a g n o s i so f
skeletal metastasis was investigated using the card
record, predominantly in the form of an inquiry card
that was given to patients. In the inquiry card, patients
were asked about the presence or absence of pain, and
sites of pain. The grade of pain (visual-analog scale) was
obtained from a limited number of patients. Therefore,
the focus was on the presence or absence of pain. The
values for tumor markers (carcinoembryonic antigen,
CEA, and cancer antigen 15-3, CA 15-3) when osseous
metastasis was diagnosed were classified as below, equal
to or above the reference value. Reference values were
5.0 ng/ml for CEA and 30 ng/ml for CA 15-3.
Factors at initial therapy
The following factors were used in a Cox proportional
hazards mode: age at surgery (Age), menstruation state,
breast tumor (T) with minor modification (T2 tumors
were classed as small (2.1-3.0 cm) or large (3.1-5.0 cm)),
clinical and pathological lymph node state (N and pN),
histopathology, and estrogen receptor and progesterone
receptor status. Tumors were classified as: in situ, non-
invasive cancer; T0, no detectable tumor; T1, ≤ 2.0 cm;
T2 small, 2.1-3.0 cm; T2 large, 3.1-5.0 cm; T3, ≥ 5.1 cm;
T4, any size with direct extension to chest wall or skin
according to the 2002 UICC-TNM classification [16].
Histological classification was performed according to
the criteria of the Japanese Breast Cancer Society [17],
which differs from the WHO classification. The
Japanese system divides invasive ductal carcinoma not
otherwise specified (NOS) according to the WHO classi-
fication into three categories based on morphology:
papillotubular, solid-tubular and scirrhous carcinoma
[17,18]. Lymph node status can be classified by two
methods: N, clinical or preoperative classification; and
pN, pathological classification. Pathological classification
was used in this study as it is more accurate than clini-
cal classification. The ER status of a tumor was classed
as positive when the concentration was greater than 13
fmol/mg cytosol protein. The PgR status of a tumor was
defined as positive when the concentration was greater
than 10 fmol/mg cytosol protein.
Analysis and statistical methods
Data were analyzed as follows. First, the percentages of
patients with or without pain and with or without eleva-
tion of CEA or CA15-3 at the diagnosis of skeletal
metastasis were calculated, and the time from surgery to
the appearance of skeletal metastasis with or without
pain was calculated and tested using the Mann-Whitney
U test. Secondly, Kaplan-Meier’s method with a log-rank
test was used to compare SREs (pathological fracture,
spinal cord paralysis, hypercalcemia, radiation therapy
for osseous metastasis, orthopedic surgery for bone
metastasis, and the use of morphine for pain) and survi-
val (cause-specific death, CSD) in patients with and
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fore, two types of events were used for the analysis: SRE
and CSD. Deaths due to other causes were treated as
censored. The starting point of the study was the date
of diagnosis of skeletal metastasis. Thirdly, a Cox pro-
portional hazards regression model was used to investi-
gate whether the presence of pain was a significant
factor using univariate and multivariate analysis. The
proportionality of each hazard was confirmed by plot-
ting a log-minus-log curve. Multivariate Cox propor-
tional hazards regression analysis was conducted using a
backward stepwise method (the statistical level of signifi-
cance determined with the Wald test was set at P <
0.10). All analyses were performed using SAS version
8.2 (SAS Institute Inc., Cary NC). Finally, as a lead-time
effect could influence the results, a similar analysis (sec-
ond and third steps) using the initial surgery date as a
starting point was also performed.
In addition, the number of bone metastatic lesions
(solitary or multiple) at the time of diagnosis of skeletal
metastasis was an important factor. The importance of
this factor was reported [14] as solitary bone metastasis
was a significant favorable prognostic factor compared
with multiple bone lesions at initial presentation. Strati-
fied sub-analysis was conducted on groups of individuals
with a solitary bone lesion or multiple bone lesions at
their initial presentation of skeletal metastasis.
This retrospective study was approved by the Institu-
tional Review Board. Informed consent was not required
as this was a retrospective study.
Results
Of 668 patients who developed skeletal metastasis, the
pain status was unknown in 2 patients, therefore 666
patients were included in this study. Of the total num-
ber of individuals, 396 (59.5%) did not complain of pain
and 270 (40.5%) did. CEA values were available for 647
patients; 412 (63.7%) had a normal value and 235
(36.3%) were above the reference value. CA15-3 values
were available for 649 patients; 391 (60.2%) had normal
values and 258 (39.8%) were above the reference value.
In 396 osseous metastasis patients without pain, 60 had
elevated CEA without elevation of CA 15-3, 55 had ele-
vated CA 15-3 without elevation of CEA, 80 presented
with elevation of both CEA and CA 15-3, and in 201
patients both CEA and CA 15-3 were within normal
limits. There were 187 (28.1%) patients who did not pre-
sent with both bone pain and tumor marker elevation.
The patients’ characteristics are presented in addi-
tional file 1. With the exception of CA15-3 and number
of metastatic lesions (solitary or multiple), there was no
significant difference between patients with and without
pain regarding the factors noted at the start of therapy.
The mean period from surgery to diagnosis of skeletal
metastasis was 1262 days (median 1031 days) for
patients without pain and 1268 days (median 921 days)
for patients with pain. There was no statistical difference
in the period from surgery to diagnosis between patients
with or without pain (Mann-Whitney U test p = 0.785).
The mean period from diagnosis of skeletal metastasis
to development of SREs was 657 days (median 395
days) for patients without pain and 281 days (median 45
days) for patients with pain. There was a statistical dif-
ference in the period from diagnosis to development of
SREs between patients with and without pain (Mann-
Whitney U test p < 0.0001).
The numbers of patients with and without pain in
each SRE are presented in additional file 2.
The Kaplan-Meier curves for SREs in patients with
and without pain are presented in figure 1. The starting
point was the date of diagnosis of skeletal metastasis.
Patients without pain had fewer SREs than those with
pain (log-rank test: p < 0.001). Figure 2 shows Kaplan-
Meier curves for survival (CSD) in patients with and
without pain. Patients without pain survived longer than
those with pain (log-rank test: p <0.001). The results of
Cox’s proportional hazard analysis regarding SRE are
g i v e ni na d d i t i o n a lf i l e3 .P r e s e n c eo ra b s e n c eo fp a i n
was a significant factor in both univariate analysis (base:
no pain, hazard ratio = 2.331, 95% CI 1.930-2.815) and
multivariate analysis (hazard ratio = 2.243, 95% CI
1.815-2.773). The results of Cox’s proportional hazard
analysis regarding survival (CSD) are presented in addi-
tional file 4. Presence or absence of pain was a signifi-
cant factor in both univariate analysis (base: no pain,
hazard ratio = 1.441, 95% CI 1.211-1.715) and multivari-
ate analysis (hazard ratio = 1.535, 95% CI 1.263-1.866).
Figures 3 and 4 show Kaplan-Meier curves for SRE
and survival (CSD) in patients without and with pain;
the starting point was the date of initial surgery. These
analyses (from the date of surgery) were carried out to
neglect the lead-time effect of diagnosis. Patients with-
out pain had fewer SREs than those with pain (log-rank
test: p < 0.001). Patients without pain survived longer
than those with pain (log-rank test: p =0 . 0 0 7 ) .C o x ’s
proportional hazard analysis was performed for SRE and
survival (CSD) from the date of surgery. The presence
or absence of pain was a significant factor in both uni-
variate analysis (base: no pain, hazard ratio = 1.691, 95%
CI 1.402-2.040) and multivariate analysis (hazard ratio =
1.646, 95% CI, 1.343-2.018) with regard to SRE. Regard-
ing survival (CSD), presence or absence of pain was a
significant factor in both univariate analysis (base: no
pain, hazard ratio = 1.268, 95% CI, 1.066-1.509) and
multivariate analysis (hazard ratio = 1.365, 95% CI,
1.128-1.651).
The Kaplan-Meier curves for patients with or without
pain are presented in figure 5. Patients with a solitary
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analyzed separately. This analysis was performed using
SRE and CSD as events and the date of diagnosis of
bone metastasis as the starting point. In patients with a
solitary bone lesion, individuals with pain showed a sig-
nificantly higher incidence of SRE than those without
pain but showed no significant differences in terms of
CSD. In patients with multiple bone lesions, individuals
with pain showed a significantly higher incidence of SRE
and CSD than those with no pain but CSD incidence
was less than that of SRE.
Discussion
Bone pain is commonly associated with skeletal metasta-
sis. However, in this study approximately 60% of
patients did not complain of bone pain at diagnosis.
Patients who developed skeletal metastasis without pain
had fewer SREs and longer survival (CSD) than those
with pain; these differences were statistically significant.
The results were consistent irrespective of the analysis
method used (Kaplan-Meier, log-rank test and Cox’s
proportional hazard model analysis). Cox’s proportional
hazards regression analysis using SRE and CSD as end-
points demonstrated that hazard ratios (univariate) of all
significant factors were higher in value for CSD than for
bone pain; this was also the case in multivariable
analysis. Hazard ratio of bone pain was 2.331 for the
SRE event, 1.441 for the CSD event (univariable analy-
sis), 2.243 for SRE and 1.535 for CSD (multivariable).
The presence of bone pain predicted SRE more accu-
rately than CSD. Bone pain could be an important fac-
tor in predicting SRE, and other factors could be of
more use in predicting CSD.
This research was a cohort study in a single institute
that compared SRE and CSD of asymptomatic and
symptomatic patients who had developed osseous
metastasis. This type of comparison can be biased by
lead time (early detection simply increases the period
during which osseous metastasis is observed) and
length time (patients with a long preclinical phase and
therefore presumably less aggressive metastasis are
l i k e l yt ob ed e t e c t e db yp e r i o d i cb o n es u r v e y ) .D i f f e r -
ences in SREs and survival (CSD) could be due to the
lead time bias. However, additional analysis taking the
starting point as the date of surgery produced similar
results. There was no difference in the chronological
period of diagnosis of skeletal metastasis between
patients with or without pain (data not shown), indi-
cating that therapy after the diagnosis of skeletal
metastasis did not differ between these groups of
patients. There was no difference in the use of bispho-
sphonates for patients without pain and those with
Figure 1 Kaplan-Meier curves for skeletal-related events (SRE) in patients with and without pain. Starting point was the date of diagnosis
of skeletal metastasis. SRE fractions are shown for skeletal metastasis patients without pain (black line) and with pain (gray line). A log-rank test
demonstrated a statistically significant difference between the two groups (p < 0.001). Starting point was the date of diagnosis of skeletal
metastasis.
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fewer SREs and longer survival (CSD) were not due to
the lead time bias. Length time bias could not be
eliminated from this study even though the time from
initial surgery to diagnosis of osseous metastasis was
no different in patients with or without pain. Patients
with painful bone metastases could have different dis-
ease biology from asymptomatic individuals (more
aggressive recurrence, rapid growth, higher disease
burden, more lytic lesions), which could account for
their poor prognosis. The results presented herein do
not predict that routine bone surveys will detect more
asymptomatic patients and improve their outcome.
However, the results do reveal that asymptomatic
patients diagnosed with skeletal metastasis had lesser
SRE and CSD than symptomatic patients. Kohno et al.
reported that the SRE rate was higher among patients
with pathological fractures before diagnosis than in
patients with no prior fracture [12], and this could
relate to the fact that the SRE rate was higher in
patients with bone pain at the time of diagnosis of ske-
letal metastasis than in patients with no pain. Patients
with skeletal metastasis but no bone pain (bone pain
could be the result of micro-fractures at skeletal
metastasis) should present with a lower SRE than
patients with bone pain.
Drawbacks with this retrospective study include using
a database of breast cancer patients in our institute,
where data collection began approximately 30 years ago.
The records lacked several important pieces of informa-
tion including tumor grade and HER2/neu status, and it
employed the local (Japanese) pathological classification
system. A second database was utilized for data analysis
of skeletal metastasis in breast cancer patients. This
database lacked information regarding the type of skele-
tal metastasis (lytic, blastic, mixed type), and both data-
bases lacked information regarding the pain condition of
individuals. Patients’ records (cards) were checked for
t h ep r e s e n c eo ra b s e n c eo fp a in at diagnosis of skeletal
metastasis but there was no detailed information about
the pain condition of individuals.
Therapy for breast cancer has changed over time with
the advancement of chemotherapeutic agents and their
combination, hormones and molecular targeting agents
(HER2/neu). The concept of standard therapy for skele-
tal metastasis has changed with the advent of bispho-
sphonates. In Japan, bisphosphonates were first
approved for use in the treatment of skeletal metastasis
Figure 2 Kaplan-Meier curves for survival (cause-specific death, CSD) in patients with and without pain. Starting point was the date of
diagnosis of skeletal metastasis. CSD fractions are presented for patients without pain (black line) and with pain (gray line). A log-rank test
demonstrated a statistically significant difference between the two groups (p < 0.001). Starting point was the date of diagnosis of skeletal
metastasis.
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Page 5 of 9Figure 3 Kaplan-Meier curves for skeletal-related events (SRE) in patients with and without pain. Starting point was the date of initial
surgery. SRE fractions are presented for skeletal metastasis patients without pain (black line) and with pain (gray line). A log-rank test
demonstrated a statistically significant difference between the two groups (p < 0.001). Starting point was the date of initial surgery.
Figure 4 Kaplan-Meier curves for survival (cause-specific death, CSD) in patients with and without pain. Starting point was the date of
initial surgery. CSD fractions are presented for patients without pain (black line) and with pain (gray line). A log-rank test demonstrated a
statistically significant difference between the two groups (p = 0.07). Starting point was the date of initial surgery.
Koizumi et al. BMC Cancer 2010, 10:423
http://www.biomedcentral.com/1471-2407/10/423
Page 6 of 9at the end of 2004, and actual use began in 2005. There-
fore, there were limited data regarding the use of
bisphosphonates in this study and this prevented analy-
sis of the impact of bisphosphonate treatment. The
strategy of using radiotherapy for treating skeletal
metastasis changed during the study period. The inclu-
sion of radiotherapy treatment in the SRE classification
could result in an overestimation of the incidence of
SRE in this study. We have also performed another ana-
lysis in which first RT was not regarded as SRE and RT
at least three months apart from first RT was counted
as SRE. Although the distribution of kinds of SREs has
been changed (additional file 5), the results of statistical
analyses [Cox analysis (additional file 6) and Kaplan
Meier analysis (data not shown)] were similar.
Patients were screened using periodic bone scans and
more than 50% of patients (396/666, 59.5%) were
diagnosed as having skeletal metastasis without pain.
This is in contrast to other reports in which only a
small percentage of patients were diagnosed with skele-
tal metastasis without pain. Front et al. reported that
21/66 (21%) patients did not have bone pain at diagnosis
[19]. This difference could be due to the screening pro-
tocol used for skeletal metastasis, and advances in ima-
ging modalities such as computed tomography and
magnetic resonance imaging, which were used to con-
firm the presence or absence of skeletal metastasis.
Two randomized clinical trials (RCT) regarding
breast cancer follow-up were published in 1994,
although the studies were conducted almost 20 years
ago. They concluded that regular physical examina-
tions and annual mammography were as effective as
more intensive approaches, based on laboratory and
imaging tests in terms of timelessness of recurrence
Figure 5 Kaplan-Meier curves of SRE and CSD in patients with (gray line) and without pain (black line). Upper row figures indicate the
analysis using SRE as an event. Lower row figures indicate the analysis using CSD as an event. Left line figures indicate the analysis in patients
with a solitary bone lesion at the date of skeletal metastasis diagnosis, and right line figures indicate patients with multiple bone lesions. Starting
point was the date of diagnosis of skeletal metastasis. Black lines indicate patients without pain and gray lines indicate patients with pain. A log-
rank test in each patient group with solitary bone lesion and SRE event, solitary bone lesion and CSD event, multiple bone lesions and SRE
event, and multiple bone lesions and CSD event were performed with c2 values 27.4 (p < 0.0001), 0.8 (p = 0.36), 48.8 (p < 0.0001), and 15.8
(p < 0.0001), respectively.
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There have been no studies addressing this topic since
then. However, the diagnosis and therapy of skeletal
metastasis in breast cancer have advanced considerably
since the two RCTs were conducted, and SRE was not
used as an endpoint in those trials. Therefore, the
results of the RCTs and the present study cannot be
compared. Carrying out a RCT with SRE as an end-
point could be worthwhile.
Research into a new method of detecting skeletal
metastasis using bone metabolic markers is underway
[20]. Although the sensitivity of bone metabolic markers
in detecting skeletal metastasis is currently insufficient,
research into new markers is ongoing [20-22]. Another
new technique used to detect metastasis, including ske-
letal metastasis, is positron emission tomography (PET).
A number of publications conclude that PET is a good
method for the detection of metastasis [23-25]. It is
likely that bone surveys will be undertaken using meth-
ods other than bone scans, and that the clinical impact
of bone metastasis will be clarified.
Conclusions
Breast cancer patients who were diagnosed with skeletal
metastasis without pain had fewer SREs than those with
pain, and pain was a predictor of SRE. Other factors
were predictors for CSD. Detection of skeletal metastasis
in patients who do not have bone pain leads to a lower
incidence of SREs. However, the data did not support a
recommendation for bone surveys in the follow-up of
breast cancer patients. These results could lead to a new
randomized clinical trial to investigate whether early
detection of skeletal metastasis has clinical significance.
Additional material
Additional file 1: Patient demographics and tumor characteristics.
Additional file 1 shows patients demographics and tumor characteristics.
Additional file 2: Skeletal related events and pain. Additional file 2
shows skeletal related events with and without pain.
Additional file 3: Cox propotional hazard analysis as predicotors of
SRE. Additional file 3 shows the results of Cox propotional hazard
analysis as predicotors of SRE.
Additional file 4: Cox propotional hazard analysis as predicotors of
CSD. Additional file 4 shows the results of Cox propotional hazard
analysis as predicotors of CSD.
Additional file 5: Revised skeletal related events* and pain.
Additional file 5 shows revised skeletal related events and pain. Revised
skeletal related events (SREs) were the events where the first RT was not
counted as events. RT at least 3 months apart from the first RT was
regarded as revised SRE.
Additional file 6: Cox propotional hazard analysis as predicotors of
revised SRE. Additional file 6 shows the results of Cox proportional
hazard analysis as predictors of revised SRE. Revised skeletal related
events (SRE) were the events where the first RT was not counted as
events. RT at least 3 months apart from the first RT was regarded as
revised SRE.
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